Mericitabine
- Generic Name
- Mericitabine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26FN3O6
- CAS Number
- 940908-79-2
- Unique Ingredient Identifier
- TA63JX8X52
- Background
Mericitabine has been investigated for the treatment of Hepatitis C, Chronic.
Mericitabine is a polymerase inhibitor being developed for the treatment of chronic hepatitis C. Mericitabine is a prodrug of PSI-6130, which demonstrated excellent potency in preclinical studies. PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for hepatitis C viral replication.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT01482403
A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT01482390
- Locations
- 🇺🇸
Carolina'S Center For Liver Disease, Statesville, North Carolina, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
🇺🇸Birmingham Gastro Associates, P.C., Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.